We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
Read MoreHide Full Article
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL - Free Report) or Liquidia Corporation (LQDA - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Exelixis has a Zacks Rank of #1 (Strong Buy), while Liquidia Corporation has a Zacks Rank of #2 (Buy) right now. Investors should feel comfortable knowing that EXEL likely has seen a stronger improvement to its earnings outlook than LQDA has recently. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
EXEL currently has a forward P/E ratio of 12.65, while LQDA has a forward P/E of 62.04. We also note that EXEL has a PEG ratio of 0.65. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. LQDA currently has a PEG ratio of 1.13.
Another notable valuation metric for EXEL is its P/B ratio of 5.33. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, LQDA has a P/B of 158.47.
Based on these metrics and many more, EXEL holds a Value grade of B, while LQDA has a Value grade of D.
EXEL sticks out from LQDA in both our Zacks Rank and Style Scores models, so value investors will likely feel that EXEL is the better option right now.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
EXEL or LQDA: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL - Free Report) or Liquidia Corporation (LQDA - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Exelixis has a Zacks Rank of #1 (Strong Buy), while Liquidia Corporation has a Zacks Rank of #2 (Buy) right now. Investors should feel comfortable knowing that EXEL likely has seen a stronger improvement to its earnings outlook than LQDA has recently. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
EXEL currently has a forward P/E ratio of 12.65, while LQDA has a forward P/E of 62.04. We also note that EXEL has a PEG ratio of 0.65. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. LQDA currently has a PEG ratio of 1.13.
Another notable valuation metric for EXEL is its P/B ratio of 5.33. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, LQDA has a P/B of 158.47.
Based on these metrics and many more, EXEL holds a Value grade of B, while LQDA has a Value grade of D.
EXEL sticks out from LQDA in both our Zacks Rank and Style Scores models, so value investors will likely feel that EXEL is the better option right now.